External genital endometriosis post-surgery hemostasis parameters

Introduction. Endometriosis is one of the common diseases with poorly elucidated underlying nature and pathogenetic mechanisms. Clinical trials suggest that women suffering from it have hemostasis disorders. However, the severity of relevant changes and their origin remain debated.

Aim: to study the dynamics of hemostasis system parameters in patients underwent surgical treatment of external genital endometriosis (EGE).

Materials and Methods. A total of 120 women were enrolled into the prospective interventional comparative controlled study: 40 patients with EGE scheduled for surgical treatment (main group), 40 patients with other benign gynecological diseases requiring surgical intervention (comparison group), and 40 apparently healthy women (control group). Нemostasis system status was assessed based on the results of 3 visits during 3 month-follow-up by assessing the following biomarkers: metalloproteinase ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), von Willebrand factor (vWF), D-dimer, protein C, antithrombin III (AT-III), activated partial thromboplastin time (APTT) and Рarus-test values.

Results. Prior to surgery, among EGE women a subclinical but significant increase in procoagulant biomarkers was observed compared to other groups: vWF – 1.24 [1.17–1.35] U/ml, D-dimer – 173.5 [73.5–221.23] ng/ml. Evaluation of the remaining parameters showed no clinical significance of the observed changes. The endometriosis-related surgical intervention was accompanied by increase in specific procoagulant factors a week post-treatment apparently associated with surgical manipulations. However, 3 months later, hemostasis system status partially normalized as revealed by lower biomarkers examined, which in some cases were significantly decreased compared to those observed before surgery. At the same time, differences between the study groups remained statistically significant.

Conclusion. Patients with EGE were noted to have a subclinical risk of thrombogenesis. Upon this, surgical treatment and rehabilitation during recovery period allowed to improve overall state of the hemostasis system, thereby reducing a thrombogenesis risk.

1. Endometriosis. [Endometrioz]. World Health Organization, 2023. (In Russ.). Available at: https://www.who.int/news-room/fact-sheets/detail/endometriosis. [Accessed: 12.09.2024].

2. Rogers P.A.W., D’Hooghe T.M., Fazleabas A. et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16(4):335–46. https://doi.org/10.1177/1933719108330568.

3. Abbas S., Ihle P., Köster I., Schubert I. Prevalence and incidence of diagnosed endometriosis and risk of endometriosis in patients with endometriosis-related symptoms: findings from a statutory health insurance-based cohort in Germany. Eur J Obstet Gynecol Reprod Biol. 2012;160(1):79–83. https://doi.org/10.1016/j.ejogrb.2011.09.041.

4. Ballard K.D., Seaman H.E., de Vries C.S., Wright J.T. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study – Part 1. BJOG. 2008;115(11):1382–91. https://doi.org/10.1111/j.1471-0528.2008.01878.x.

5. Eisenberg V.H., Weil C., Chodick G., Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55–62. https://doi.org/10.1111/1471-0528.14711.

6. Pugsley Z., Ballard K. Management of endometriosis in general practice: the pathway to diagnosis. Br J Gen Pract. 2007;57(539):470–6.

7. Sampson J.A. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14(4):422–69. https://doi.org/10.1016/S0002-9378(15)30003-X.

8. Brosens I., Benagiano G. Is neonatal uterine bleeding involved in the pathogenesis of endometriosis as a source of stem cells? Fertil Steril. 2013;100(3):622–3. https://doi.org/10.1016/j.fertnstert.2013.04.046.

9. Burney R.O., Giudice L.C. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–9. https://doi.org/10.1016/j.fertnstert.2012.06.029.

10. Brosens I.A. Endometriosis – a disease because it is characterized by bleeding. Am J Obstet Gynecol. 1997;176(2):263–7. https://doi.org/10.1016/s0002-9378(97)70482-4.

11. Sharma R.P., Delly F., Marin H., Sturza S. Endometriosis causing lower extremity deep vein thrombosis – case report and review of the literature. Int J Angiol. 2011;18(4):199–202. https://doi.org/10.1055/s-0031-1278354.

12. Chiaramonte R., Castorina S., Castorina E.G. et al. Thrombosis of iliac vessels, a rare complication of endometriosis: Case report and review of literature. J Adv Res. 2017;8(1):1–5. https://doi.org/10.1016/j.jare.2016.10.007.

13. Ding D., Liu X., Guo S.W. Further evidence for hypercoagulability in women with ovarian endometriomas. Reprod Sci. 2018;25(11):1540–8. https://doi.org/10.1177/1933719118799195.

14. Ding S., Lin Q., Zhu T. et al. Is there a correlation between inflammatory markers and coagulation parameters in women with advanced ovarian endometriosis? BMC Womens Health. 2019;19:169. https://doi.org/10.1186/s12905-019-0860-9.

15. Chen Z.Y., Zhang L.F., Zhang Y.Q. et al. Blood tests for prediction of deep endometriosis: а case-control study. World J Clin Cases. 2021;9(35):10805–15. https://doi.org/10.12998/wjcc.v9.i35.10805.

16. Seckin B., Ates M.C., Kirbas A., Yesilyurt H. Usefulness of hematological parameters for differential diagnosis of endometriomas in adolescents/young adults and older women. Int J Adolesc Med Health. 2018;33(2). https://doi.org/10.1515/ijamh-2018-0078.

17. Turgut A., Hocaoglu M., Ozdamar O. et al. Could hematologic parameters be useful biomarkers for the diagnosis of endometriosis? Bratisl Lek Listy. 2019;120(12):912–8. https://doi.org/10.4149/BLL_2019_153.

18. Viganò P., Ottolina J., Sarais V. et al. Coagulation status in women with endometriosis. Reprod Sci. 2018;25(4):559–65. https://doi.org/10.1177/1933719117718273.

19. Wu Q., Ding D., Liu X., Guo S.W. Evidence for a hypercoagulable state in women with ovarian endometriomas. Reprod Sci. 2015;22(9):1107–14. https://doi.org/10.1177/1933719115572478.

20. Sorokina A.V. Endometriosis. [Endometrioz]. Medicinskaya sestra. 2010;(8):21–2. (In Russ.).

21. Myagchenkova K.I., Khashchenko E.P., Uvarova E.V. Psychoemotional characteristics and pain symptoms in patients with genital endometriosis in early reproductive age. [Psihoemocional'nye osobennosti i bolevaya simptomatika u pacientok, stradayushchih genital'nym endometriozom v rannem reproduktivnom vozraste]. Reproduktivnoe zdorov'e detej i podrostkov. 2021;17(2):41–50. (In Russ.). https://doi.org/10.33029/1816-2134-2020-17-2-41-50.

22. Chang H.-H., Chiang B.-L. The diagnosis and classification of autoimmune coagulopathy: an updated review. Autoimmun Rev. 2014;13(4–5):587–90. https://doi.org/10.1016/j.autrev.2014.01.032.

23. Bacon J.L. Abnormal uterine bleeding: current classification and clinical management. Obstet Gynecol Clin North Am. 2017;44(2):179–93. https://doi.org/10.1016/j.ogc.2017.02.012.

24. Williams B., Zou L., Pittet J.F., Chao W. Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies. Anesth Analg. 2024;138(4):696–711. https://doi.org/10.1213/ANE.0000000000006888.

25. Khasanova Yu.V., Nelaeva A.A., Galkina A.B., Medvedeva I.V. The role of coagulation and inflammation in the development of diabetic nephropathy in patients withdiabetes mellitus type 2. [Rol' koagulyacii i vospaleniya v razvitii diabeticheskoj nefropatii u bol'nyh saharnym diabetom 2 tipa]. Saharnyj diabet. 2012;(1):31–4. (In Russ.). https://doi.org/10.14341/2072-0351-5976.

26. Koloskov A.V., Mangushlo A.A. Metalloprotease Adamts-13. [Metalloproteaza Adamts-13]. Gematologiya i transfuziologiya. 2019;64(4):471–82. (In Russ.). https://doi.org/10.35754/0234-5730-2019-64-4-471-482.

27. Zhao K., Qu P. Noninvasive evaluation of ovarian endometriosis: a single-center experience. Ann Palliat Med. 2021;10(4):4728–35. https://doi.org/10.21037/apm-21-481.

28. Ling X., Wang T. Diagnostic and prognostic value of coagulation-related factors in endometriosis. Am J Transl Res. 2022;14(11):7924–31.

29. Metcalf R.L., Fry D.J., Swindell R. et al. Thrombosis in ovarian cancer: a case control study. Br J Cancer. 2014;110(5):1118–24. https://doi.org/10.1038/bjc.2014.3.

30. Greco P.S., Bazzi A.A., McLean K. et al. Incidence and timing of thromboembolic events in patients with ovarian cancer undergoing neoadjuvant chemotherapy. Obstet Gynecol. 2017;129(6):979–85. https://doi.org/10.1097/AOG.0000000000001980.

31. Mansurova A.S., Krasil'nikov S.E., Voitcitckii V.E. Double threat:Ovarian cancer and thrombotic complications. [Dvojnaya ugroza. Rak yaichnikov i tromboticheskie oslozhneniya]. Rossijskij onkologicheskij zhurnal. 2021;26(3):101–6. (In Russ.). https://doi.org/10.17816/onco107326.

32. Lugovskii E.V., Kolesnikova I.N., Platonova T.N. et al. Simultaneous quantification of soluble fibrin and D-dimer in blood plasma for the assessment of the threat of thrombosis. [Odnovremennoe kolichestvennoe opredelenie rastvorimogo fibrina i D-dimera v plazme krovi dlya ocenki ugrozy tromboobrazovaniya]. Klinicheskaya medicina. 2013;91(11):38–44. (In Russ.).